arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

IRIDEX CORP

IRIX
$0.70 ▲ +0.01 (+0.72%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

IRIDEX CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.9M
Dividend Yield —
Revenue Growth 8.2% ↗
Op. Margin -4.9% ↗
ROIC -52.9% ↗
FCF / Share $-0.13 ↗
Trailing P/E —
Price / Book 2.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$52.67M
↑ +8.2% —
Net Income Profit after all expenses
$-4.44M
↑ +50.2% —
Operating Margin Operating profit as % of sales
-4.9%
↑ +71.4% 17th
FCF / Share Free cash flow per share
$-0.13
↑ +70.0% —
Long-Term Debt Long-term obligations
$1.00M
↓ -19.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
14
Returns ↓
8
Financial Health ↓
18
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters